Multiscale modeling of angiogenic tumor growth, progression, and therapy


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

A mathematical model of angiogenic tumor growth in tissue with account of bevacizumab therapy was developed. The model accounts for convective flows that occur in dense tissue under active division of tumor cells, as well as the migration and proliferation dichotomy of malignant cells, which depends on the concentrations of major metabolites, such as oxygen and glucose. Tumor cells wich are in a state of metabolic stress produce vascular endothelial growth factor, which stimulates angiogenesis. To establish the relationship between the capillary network density and oxygen supply, a separate model of stationary blood flow in the capillary network was developed and investigated. A numerical study of the tumor-growth model showed that antiangiogenic bevacizumab treatment of tumors of the diffuse type reduces the total number of their cells, but practically does not affect the rate of their invasion into normal tissues. At the same time, it was found that the growth of dense tumors may be non-monotonic in a rather wide range of parameters. It was shown that in this case bevacizumab therapy stabilizes and significantly inhibits tumor growth, while its local-in-time efficiency is sensitive to the time that it begins.

作者简介

M. Kuznetsov

Lebedev Physical Institute

Email: kolobov@lpi.ru
俄罗斯联邦, Leninskiy pr. 53, Moscow, 119991

N. Gorodnova

Institute of Numerical Mathematics

Email: kolobov@lpi.ru
俄罗斯联邦, ul. Gubkina 8, Moscow, 119333

S. Simakov

Institute of Numerical Mathematics; Moscow Institute of Physics and Technology

Email: kolobov@lpi.ru
俄罗斯联邦, ul. Gubkina 8, Moscow, 119333; Institutskiy per. 9, Dolgoprudny, Moscow oblast, 141701

A. Kolobov

Lebedev Physical Institute; Institute of Numerical Mathematics

编辑信件的主要联系方式.
Email: kolobov@lpi.ru
俄罗斯联邦, Leninskiy pr. 53, Moscow, 119991; ul. Gubkina 8, Moscow, 119333

补充文件

附件文件
动作
1. JATS XML

版权所有 © Pleiades Publishing, Inc., 2016